bendamustine / Generic mfg. 
Welcome,         Profile    Billing    Logout  

194 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bendamustine / Generic mfg.
2017-003593-13: UK CLL Long Term Follow Up Study

Ongoing
4
800
Europe
Obinutuzumab, Fludarabine, Fludarabine (IV), Cyclophospamide (oral), Cyclophosphamide (IV), Rituximab, Bendamustine, Mitoxantrone, Alemtuzumab, Ofatumumab, Concentrate for solution for infusion, Film-coated tablet, Powder for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Obinutuzumab, Fludarabine (oral), Ofatumumab
University of Leeds, Napp Pharmaceuticals
Chronic lymphocytic leukaemia (CLL), Chronic lymphocytic leukaemia (CLL), Diseases [C] - Cancer [C04]
 
 
GAZELLE, NCT03817853: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Completed
4
114
Europe, Japan, US, RoW
Obinutuzumab, GA101, RO5072759, Bendamustine, Cyclophosphamide, Doxorubicin, Prednisone/Prednisolone/Methylprednisolone, Vincristine
Hoffmann-La Roche
Advanced Follicular Lymphoma
08/20
01/23
ChiCTR2000033337: R-BAC regimen in the treatment of relapsed and refractory diffuse large B-cell lymphoma

Not yet recruiting
4
50
 
Rituximab, Bendamustine combined with Cytarabine
Xiangya Second Hospital of Central South University; Xiangya Second Hospital of Central South University, Self-raised
Relapsed and refractory diffuse large B-cell lymphoma
 
 
ChiCTR2100048232: Clinical study of BeEAM (bendamustine, etoposide, cytarabine, melphalan) regimen for preconditioning before lymphoma autotransplantation

Not yet recruiting
4
50
 
Bendamustine + cytarabine + etoposide + macfaran
He'nan Provincial People's Hospital; He'nan Provincial People's Hospital, self-funded
lymphoma
 
 
ChiCTR2000039605: Bendamustine in the treatment of newly diagnosed indolent non-Hodgkin B-cell lymphoma: a real-world study

Recruiting
4
280
 
NA
Harbin First Hospital/ Peking University Cancer Hospital; Harbin Institute of Hematology and Oncology, Beijing Health Allicance Charitable Foundation
Indolent non-Hodgkin B-cell lymphoma
 
 
ChiCTR2100043720: The comparison between bendamustine with melphalan and melphalan alone as autologous hematopoietic stem cell transplantation conditioning regimen in multiple myeloma.

Recruiting
4
236
 
bendamustine and melphalan ;melphalan alone
Department of Hematology and oncology, Cancer Hospital Affiliated to Chongqing University; Cancer Hospital Affiliated to Chongqing University, None
Multiple meyloma
 
 
NCT04842318: Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

Recruiting
4
789
RoW
BR for 6 cycles +R for 8 cycles, RCHOP for 6 cycles +R for 8 cycles, R2 for 6 cycles + R2 maintenance
Ruijin Hospital
Follicular Lymphoma
03/23
03/24
ChiCTR2100046675: The efficacy on the combination of bendamustine with melphalan as autologous hematopoietic stem cell transplantation conditioning regimen in multiple myeloma

Recruiting
4
56
 
Bendamustine plus melphalan
The Department of Hematology of the Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University, None
Multiple meyloma
 
 
ChiCTR2100048305: The efficacy on the combination of bendamustine with melphalan as autologous hematopoietic stem cell transplantation preconditioning regimen in multiple myeloma.

Not yet recruiting
4
56
 
Bendamustine plus melphalan
The Department of Hematology, West China Hospital, Sichuan University; West China Hospital, Sichuan University, None
Multiple meyloma
 
 
ChiCTR2100047782: Effect of bendamustine combined with melphalan on preconditioning before autologous hematopoietic stem cell transplantation for multiple myeloma

Not yet recruiting
4
56
 
No
West China Hospital, Sichuan University; West China Hospital, Sichuan University, None
multiple myeloma
 
 
ChiCTR2200056288: A multicenter, prospective, non-random cohort study of BR±lenalidomide in the treatment of newly treated indolent B-cell lymphoma and elderly mantle cell lymphoma

Recruiting
4
60
 
bendamustine
Shandong Cancer Hospital; Shandong Cancer Hospital, self-financing
lymphoma
 
 
ChiCTR2200059910: A prospective clinical study of bendamustine/pomalidomide/bortezomib/dexamethasone (BPVd) in the treatment of patients with relapsed and refractory multiple myeloma

Recruiting
4
60
 
BDVP scheme
Department of Hematology, Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Self-funded by the department
multiple myeloma
 
 
ChiCTR2100048295: Clinical study of BeEAM (bendamustine, etoposide, cytarabine, melphalan) regimen for preconditioning before lymphoma autotransplantation

Recruiting
4
50
 
Bendamustine + cytarabine + etoposide + macfaran
He'nan Provincial People's Hospital; He'nan Provincial People's Hospital, self-funded
lymphoma
 
 
ChiCTR2300073448: Clinical study of mitoxantrone hydrochloride liposome injection combined with rituximab and bendamustine (RMB) in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a single-arm, single-center, prospective phase Ib

Not yet recruiting
4
12
 
Different doses of mitoxantrone hydrochloride liposome injection and fixed doses of rituximab, bendamustine
Chongqing University Cancer Hospital; Chongqing University Cancer Hospital, none
Relapsed and refractory diffuse large B-cell lymphoma
 
 
ChiCTR2300068152: A single arm, open label, multicenter study of zanubrutinib combined with bendamustine in newly diagnosed chronic lymphocytic leukemia / small lymphocytic lymphoma

Not yet recruiting
4
35
 
Zanubrutinib and bendamustine combination
Ruijin Hospital Shanghai Jiaotong University School of Medicine; Ruijin Hospital Shanghai Jiaotong University School of Medicine, self-funded
Chronic lymphocytic leukemia/small lymphocytic lymphoma
 
 
ACTRN12610000445077: An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL).

Active, not recruiting
3
436
 
Cephalon Inc, Cephalon Inc
Non-Hodgkin's Lymphoma
 
 
ALLIANCE A041202, NCT01886872: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Checkmark Ibrutinib + Rituxan for 1L CLL
Dec 2018 - Dec 2018: Ibrutinib + Rituxan for 1L CLL
Active, not recruiting
3
547
Canada, US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima
National Cancer Institute (NCI)
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
08/18
01/25
2017-003909-17: A trial of oral azacitidine compared to standard treatment in patients with relapsed lymphoma.

Not yet recruiting
3
86
Europe, RoW
Azacitidine, Gemzar, Bendamustine, CC-486, Tablet, Powder for infusion, Gemzar, Levact
LYSARC, LYSARC: THE LYMPHOMA ACADEMIC RESEARCH ORGANISATION, CELGENE,
Relapsed or Refractory Angioimmunoblastic T cell Lymphoma, A rare type of non-hodgkin lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT02414022: Economic Analysis of Alliance A041202 CLL Study

Checkmark Presentation of data from Alliance A041202 CLL study for CLL at ASH 2018
Dec 2018 - Dec 2018: Presentation of data from Alliance A041202 CLL study for CLL at ASH 2018
Active, not recruiting
3
55
Canada
Canadian Cancer Trials Group
Chronic Lymphocytic Leukemia
04/19
01/25
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
Oracle, NCT03593018: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Active, not recruiting
3
86
Europe
Oral azacitidine, CC-486, Romidepsin, Istodax, Bendamustine, Levact, Gemcitabine, Gemzar
The Lymphoma Academic Research Organisation, Celgene
Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma
02/21
12/24
SEQUOIA, NCT03336333 / 2017-001551-31: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Checkmark Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Jul 2021 - Jul 2021: Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Checkmark Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Active, not recruiting
3
590
Europe, US, RoW
Zanubrutinib, BGB-3111, BRUKINSA, Bendamustine, Treanda, Ribomustin, and Levact, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta, Venclyxto
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/21
09/26
2020-004554-30: A Phase 3 Study Comparing LOXO-305 to Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab

Ongoing
3
250
Europe, RoW
LOXO-305, Bendamustine Hydrochloride, Rituximab, Idelalisib, [na], Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Bendamustine Accord, Bendamustin cell pharm®, MabThera, Zydelig
Loxo Oncology Inc, LOXO ONCOLOGY INCORPORATED, Loxo Oncology Inc
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years., Diseases [C] - Cancer [C04]
 
 
SHINE , NCT01776840 / 2012-004056-11: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Checkmark Data from SHINE trial in 1L MCL at ASCO 2022
Jun 2022 - Jun 2022: Data from SHINE trial in 1L MCL at ASCO 2022
Checkmark From SHINE trial in 1L MCL
Mar 2022 - Mar 2022: From SHINE trial in 1L MCL
Completed
3
523
Europe, Canada, Japan, US, RoW
Bendamustine, Rituximab, Ibrutinib, Placebo
Janssen Research & Development, LLC, Pharmacyclics LLC.
Mantle Cell Lymphoma
06/21
06/24
ASCEND, NCT02970318 / 2015-004454-17: A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Checkmark 4-year follow up PFS data from ACEND trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 4-year follow up PFS data from ACEND trial for CLL at ASCO 2022
Checkmark From ASCEND trial for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From ASCEND trial for r/r CLL at ASH 2021
Checkmark From ASCEND trial for r/r CLL at EHA 2020
More
Active, not recruiting
3
310
Europe, Canada, US, RoW
Acalabrutinib (ACP-196), Rituximab, Idelalisib, Bendamustine
Acerta Pharma BV
Chronic Lymphocytic Leukemia
09/21
10/27
2020-003277-22: Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with Follicular Lymphoma Immunochemioterapia standard vs immunoterapia standard e chemioterapia a ridotto numero di cicli per il trattamento in prima linea di pazienti con Linfoma Follicolare

Not yet recruiting
3
602
Europe
Ciclofosfamide, Rituximab, Bendamustina, Doxorubicina, Prednisone, Vincristina, Obinutuzumab, [IMP4], [IMP1], [IMP3], [IMP2], [IMP5], [IMP8], [IMP7], [IMP6], , Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for injection/infusion, Concentrate and solvent for solution for infusion, Tablet, Solution for injection, ENDOXAN BAXTER - 200 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONI VETRO TIPO III 200 MG, MABTHERA - 1 FIALA 500 MG 50 ML, LEVACT - 2.5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE 5 FLACONCINI IN VETRO DA 100 MG, MABTHERA - 1400 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 15 ML (120MG/ML) - 1 FLACONCINO, DOXORUBICINA TEVA - 2 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10MG/5ML, PREDNISONE DOC GENERICI - "25 MG COMPRESSE" 10 COMPRESSE IN BLISTER PVC-PVDC/ALU, VINCRISTINA TEVA ITALIA - 1 MG/ML SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO DA 5 ML, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, FONDAZIONE GRADE ONLUS
High tumor burden Follicular Lymphoma Linfoma Follicolare ad elevato carico tumorale., High tumor burden Follicular Lymphoma. Linfoma Follicolare ad elevato carico tumorale., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-001234-20: A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Studio di fase 3 che confronta Pirtobrutinib (LOXO-305) con Bendamustina più Rituximab in pazienti con LLC/SLLnon trattati

Not yet recruiting
3
250
Europe, RoW
Rituximab, Bendamustine Hydrochloride, Pirtobrutinib, [na], [LOXO-305], Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Film-coated tablet, MabThera, Bendamustina Accord, Bendamustin cell pharm®
LOXO ONCOLOGY INCORPORATED, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Leucemia linfatica cronica (LLC)/linfoma linfocitico a piccole cellule, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years. La leucemia linfatica cronica (LLC)/il linfoma linfocitico a piccole cellule (SLL) è un tipo di tumore che colpisce i globuli bianchi e tende a progredire lentamente nell’arco di molti anni., Diseases [C] - Cancer [C04]
 
 
SELENE , NCT01974440 / 2013-003093-27: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Hourglass Jul 2022 - Dec 2022 : Data from SELENE trial for follicular lymphoma/MZL
Completed
3
403
Europe, Japan, US, RoW
Bendamustine, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, PCI-32765 (Ibrutinib), Placebo
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma
05/22
06/23
2021-003260-28: A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular Lymphoma Uno studio che valuta l’efficacia di axicabtagene ciloleucel rispetto alla terapia standard di cura in soggetti con linfoma follicolare recidivante/refrattario

Not yet recruiting
3
230
Europe
Bendamustine hydrochloride, Rituximab, Cyclophosphamide, Lenalidomide, Vincristine, Doxorubicin, Prednisolone, axicabtagene ciloleucel, [na], [KTE-C19], , Concentrate and solvent for concentrate for solution for infusion, Powder for concentrate for solution for infusion, Capsule, hard, Concentrate for solution for injection/infusion, Powder and solvent for concentrate for solution for infusion, Soluble tablet, Dispersion for infusion, Bendamustine 100 mg Powder for Concentrate for Solution for Infusion, MabThera, Endoxana Injection 1000 mg Powder for Solution for Injection, Revlimid, Vincristine Sulfate 1mg/ml Solution for Injection or Infusion, Doxorubicin 50 mg Powder for Concentrate for Solution for Infusion, Prednisolone, Yescarta
KITE PHARMA INC., Kite Pharma, Inc., Kite Pharma, Inc.
Relapsed and/or Refractory Follicular Lymphoma Linfoma follicolare recidivante e/o refrattario, Cancer that forms in white blood cells that has come back or has been resistant to previous therapies Cancro che si forma nei globuli bianchi che è ritornato o che è resistente alle terapie precedenti, Diseases [C] - Cancer [C04]
 
 
2022-000371-39: MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma

Ongoing
3
360
Europe
MK4280A (Favezelimab + Pembrolizumab), MK4280A, Solution for infusion, Bendamustine, Gemcitabine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT05006469: Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

Recruiting
3
10
RoW
Bendamustine, Liposome Adriamycin, Adriamycin, dexamethasone
Liao Aijun
Bendamustine, Multiple Myeloma
05/23
05/24
CHRONOS-4, NCT02626455 / 2015-001088-38: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Hourglass Jul 2022 - Sep 2022 : From CHRONOS-4 trial in indolent NHL
Terminated
3
547
Europe, Canada, Japan, US, RoW
Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone
Bayer
Lymphoma, Non-Hodgkin
09/23
11/23
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
RELEVANCE , NCT01650701 / 2011-002792-42: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

Checkmark From RELEVANCE trial in combination with rituximab
Jun 2018 - Jun 2018: From RELEVANCE trial in combination with rituximab
Checkmark Presentation from RELEVANCE for newly diagnosed follicular lymphoma at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Presentation from RELEVANCE for newly diagnosed follicular lymphoma at ASCO 2018 [screenshot]
Completed
3
1030
Europe, Canada, RoW
Rituximab, mabthera, rituxan, Lenalidomide, Revlimid, Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine
The Lymphoma Academic Research Organisation, Celgene Corporation
Follicular Lymphoma
05/17
04/24
NCT06170489: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Recruiting
3
185
RoW
JS004 in combination with Toripalimab, Bendamustine or gemcitabine
Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma
05/25
09/27
NCT06205290: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Withdrawn
3
200
Europe, US
Liso-cel, JCAR017, Breyanzi®, BMS-986387, lisocabtagene maraleucel, Idelalisib, Zydelig®, Rituximab, Rituxan®, Mabthera®, Riximyo®, Truxima®, Bendamustine, Bendeka®, Treanda®, Belrapzo®, Fludarabine, Fludara®, Bendarabin®, Cyclophosphamide, Endoxan®, Cytoxan®
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Leukemia, Lymphocytic, Chronic, B-Cell
10/31
10/31
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1080
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
05/37
05/37
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
CRISTALLO, NCT04285567: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Active, not recruiting
3
166
Europe, US, RoW
Obinutuzumab, Gazyva, RO5072759, GA101, Venetoclax, Venclexta, RO5537382, GDC-0199, Fludarabine, Cyclophosphamide, Rituximab, MabThera, Rituxan, Bendamustine, Treanda, Levact, Ribomustin
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
03/24
07/26
NCT06313996: A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Not yet recruiting
3
300
NA
Cyclophosphamide, Doxorubicin, Vincristine, Rituximab, Prednisone, Bendamustine, Lenalidomide, Fludarabine, Liso-cel, Lisocabtagene Maraleucel, BREYANZI
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Relapsed or Refractory Follicular Lymphoma
10/31
10/31
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Not yet recruiting
3
490
NA
Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo
InnoCare Pharma Inc.
Mantle Cell Lymphoma
12/34
12/35
RELEVANCE , NCT01476787: Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Checkmark Previously untreated follicular lymphoma
Jul 2013 - Jul 2013: Previously untreated follicular lymphoma
Completed
3
255
Japan, US
Rituximab, Lenalidomide, Revlimid, Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine
Celgene, The Lymphoma Academic Research Organisation
Follicular Lymphoma
04/24
04/24
NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting
3
202
NA
Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Classic Hodgkin Lymphoma
06/26
07/29
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Recruiting
3
790
Europe
Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin
The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Follicular Lymphoma
11/28
04/34
NCT06496308: Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

Recruiting
3
78
RoW
Orelabrutinib, Bendamustine, Rituximab, Venetoclax
Ruijin Hospital, Third Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Fujian Medical University Union Hospital, Yantai Yuhuangding Hospital, Huadong Hospital Affiliated with Fudan University, Shanghai, The First Affiliated Hospital of Anhui Medical University, Jiangxi Provincial Cancer Hospital, Fujian Cancer Hospital
Mantle Cell Lymphoma (MCL)
07/27
07/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
01/25
05/26
TERZO, NCT06522737: A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Not yet recruiting
3
124
NA
Duvelisib, Gemcitabine, Bendamustine
SecuraBio
Lymphoma
02/28
12/28
ECHO, NCT02972840 / 2015-005220-26: A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L MCL (based on ECHO trial)
Jul 2023 - Dec 2023: Data from ECHO trial in previously untreated MCL
Hourglass Apr 2023 - Jun 2023 : Last patient dosing of ECHO trial (NCT02972840) in previously untreated MCL
Active, not recruiting
3
635
Europe, Canada, Japan, US, RoW
Acalabrutinib, ACP-196, Calquence, Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Placebo
Acerta Pharma BV, AstraZeneca
Lymphoma, Mantle Cell
10/25
10/25
GLOBRYTE, NCT06084936: A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Recruiting
3
182
Europe, Canada, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab
Hoffmann-La Roche
Lymphoma
02/26
12/26
BGB-3111-306, NCT04002297 / 2019-000413-36: Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Active, not recruiting
3
510
Europe, Canada, Japan, US, RoW
zanubrutinib, BGB-3111, Brukinsa, bendamustine, rituximab
BeiGene
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
03/27
12/27
BELLWAVE-008, NCT05624554: A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, )

Recruiting
3
300
Europe, US, RoW
Nemtabrutinib, MK-1026, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, RITUXAN®/MabThera, Truxima, Rituximab biosimilar, Ruxience, Riabni
Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/27
03/31
MARSUN, NCT06006117: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Recruiting
3
260
Europe
Mosunetuzumab + Lenalidomide, Arm 1, - Rituximab + Lenalidomide (28-days cycles, Arm 2, - Rituximab + Bendamustine (28-days cycles), Arm 3, - Rituximab + CHOP (21-days cycles), Arm 4
The Lymphoma Academic Research Organisation
Marginal Zone Lymphoma
09/27
09/32
NCT05711628: A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn
3
334
NA
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Bendamustine, SDX-105, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Transplant Conditioning, conditioning regimen, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/28
06/28
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
OLYMPIA-1, NCT06091254: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

Recruiting
3
478
Europe, Canada, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/prednisolone, Deltasone/Omnipred, Bendamustine, Treanda
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
04/29
04/29
ZUMA-22, NCT05371093: Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

Recruiting
3
230
Europe, Japan, US
Axicabtagene Ciloleucel, Yescarta®, axi-cel, Cyclophosphamide, Fludarabine, Lenalidomide, Rituximab, Doxorubicin, Vincristine, Prednisone, Bendamustine
Kite, A Gilead Company
Relapsed/Refractory Follicular Lymphoma
10/30
10/30
2008-005859-16: First-line treatment for different subgroups of lymphomas

Ongoing
2/3
1272
Europe
Bendamustin, LA01AA09, Solution for infusion, Mabthera(R)
StiL Forschungs-GmbH, StiL Forschungs-GmbH
Indolent Non-Hodgkin Lymphomas, in particular follicular lymphomas, as well as marginal zone lymphomas, immunocytomas (Waldenström’s macroglobulinaemia) and mantle cell lymphomas, Slow growing lymph node cancers of different subtypes, Diseases [C] - Cancer [C04]
 
 
2015-000832-13: Ibrutinib for untreated mantle cell lymphoma

Ongoing
2/3
400
Europe
Ibrutinib, Rituximab, Bendamustine hydrochloride, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulphate, Prednisolone, Capsule, hard, Concentrate for solution for injection/infusion, Lyophilisate for solution for infusion, Powder for solution for infusion, Solution for infusion, Solution for injection, Tablet, Ibrutinib, doxorubicin
Plymouth Hospitals NHS Trust, Cancer Research UK, Janssen Pharmaceutica NV
Untreated symptomatic Mantle Cell Lymphoma, Untreated symptomatic Mantle Cell Lymphoma, Diseases [C] - Cancer [C04]
 
 
2021-003313-18: A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate the most effective dose and the safety of medication MK-2140 when combined with standard treatments in patients with Diffuse Large B-Cell Lymphoma who failed prior therapies.

Ongoing
2/3
420
Europe
Zilovertamab Vedotin, Gemcitabine hydrochloride, Bendamustine Chydrochloride, Oxaliplatin, MK-2140, Solution for injection, Powder for solution for infusion, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Gemcitabine SUN, Bendamustin medac, Oxaliplatin AqVida, MabThera 100mg, MabThera 500 mg
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (a type of non-Hodgkin's lymphoma, in patients who failed prior therapies), Diseases [C] - Cancer [C04]
 
 
B-MIND, NCT02763319 / 2014-004689-11: A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Hourglass Jan 2022 - Mar 2022 : From B-MIND trial in combination with bendamustine for r/r DLBCL
Checkmark Data from B-MIND trial in combination with bendamustine for r/r DLBCL
Aug 2019 - Aug 2019: Data from B-MIND trial in combination with bendamustine for r/r DLBCL
Checkmark Initiation of combo safety evaluation trial with bendamustine
May 2016 - May 2016: Initiation of combo safety evaluation trial with bendamustine
Completed
2/3
450
Europe, Canada, US, RoW
Rituximab (RTX), Rituxan, Mab Thera, Tafasitamab, Bendamustine (BEN), Levact/Treanda
Incyte Corporation, ICON Clinical Research
Diffuse Large B-cell Lymphoma
06/24
06/24
2011-000796-14: COSMIC: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL

Ongoing
2
82
Europe
Ofatumumab, Fludarabine, Cyclophosphamide, Cyclophosphamide Injection, Bendamustine, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Coated tablet, Powder for solution for injection, Powder for concentrate for solution for infusion, Arzerra (Ofatumumab), Cyclophosphamide Injection
Leeds Teaching Hospitals NHS Trust, GlaxoSmithKline
Chronic Lymphocytic Leukaemia (CLL), Leukaemia is a cancer of the white blood cells. CLL is the most common type of Leukaemia. People with CLL make too many white blood cells called lymphocytes., Diseases [C] - Cancer [C04]
 
 
2011-002307-14: Phase II salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL). Traitement de phase II par Bendamustine, Ofatumumab et MethylPrednisolone (BOMP) dans les leucémies lymphoïdes chroniques B (LLC-B) en rechute.

Ongoing
2
115
Europe
LEVACT 2,5 mg/ml powder for infusion, Ofatumumab, GSK 1841157, Powder for infusion, Concentrate and solvent for solution for infusion, Chlorhydrate de bendamustine, Arzerra ®
Groupe Est Ouest des Leucémies et Autres Maladies du Sang, Groupe Est Ouest des Leucémies et Autres Maladies du Sang
relapsed B-cell chronic lymphocytic leukemia (B-CLL). LLC B, relapsed B-cell chronic lymphocytic leukemia (B-CLL). leucémies lymphoïdes chroniques B (LLC-B) en rechute, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-005338-13: Treatment with Ofatumumab and Bendamustine in patients with lymphoma resistant to previous therapies Trattamento con Ofatumumab e Bendamustina in pazienti con linfoma resistente alle precedenti terapie

Ongoing
2
73
Europe
Bendamustine, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Arzerra
Istituto Clinico Humanitas - Humanitas Cancer Center, Regione Lombardia, GlaxoSmithKline
Non-Hodgkin's Follicular and Non-Follicular indolent lymphomas, relapsed/refractory Linfomi non Hodgkin indolenti follicolari e non follicolari, recidivati/refrattari, Indolent Lymphoma Linfomi indolenti, Diseases [C] - Cancer [C04]
 
 
2014-000130-37: Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapy STUDIO CLINICO PER VALUTARE L'EFFICACIA E LA SICUREZZA DELL'ASSOCIAZIONE DI BENDAMUSTINA-MELFALAN COME REGIME PREPARATORIO AL TRAPIANTO AUTOLOGO DI CELLULE EMATOPOIETICHE IN PAZIENTI AFFETTI DA MIELOMA MULTIPLO CHE NON HANNO RISPOSTO A PRECEDENTI TERAPIE AD ALTE DOSI.

Ongoing
2
73
Europe
Levact ® i.v., Not applicable, Powder and solution for solution for injection, Levact®
FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus), Mundipharma
Multiple myeloma Mieloma multiplo, Patients with multiple myeloma Pazienti con mieloma multiplo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01661881: Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

Checkmark Mantle cell lymphoma
Jan 2016 - Jan 2016: Mantle cell lymphoma
Active, not recruiting
2
23
US
Rituximab, Rituxan, Bendamustine, Treanda, Cytarabine, Depocyt
Dana-Farber Cancer Institute, Massachusetts General Hospital
Mantle Cell Lymphoma
02/15
03/25
2008-005687-13: Estudio Fase II abierto prospectivo no aleatorizado para valorar la combinación de rituximab, bendamustina, mitoxantrone, dexametasona (R-BMD) en pacientes con Linfoma Folicular refractarios o en recaída

Ongoing
2
60
Europe
Bendamustina, RIBOMUSTIN
GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea)
Linfoma Folicular refractarios o en recaída
 
 
2010-021451-12: Bendamustine, thalidomide and dexamethasone in relapsed/refractory myeloma

Ongoing
2
98
Europe
Bendamustine, Thalidomide, Dexamethasone, Levact, Celgene Thalidomide, Dexamethasone, Levact, Celgene Thalidomide, Dexamethasone
University of Leeds
Relpsed or refractory multiple myeloma
 
 
2010-020072-33: Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma

Ongoing
2
70
Europe
RIBOMUSTIN, VELCADE, DESAMETASONE FOSF*IM EV 1F 8MG, SOLDESAM FTE, RIBOMUSTIN, VELCADE, DESAMETASONE FOSF*IM EV 1F 8MG, SOLDESAM FTE
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
Relapsed or refractory multiple myeloma
 
 
2008-007125-39: A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation

Ongoing
2
12
Europe
Lenalidomide, Bendamustine, CC-5013, Revlimid, Revlimid
Klinik f. Innere Med., Fachabteilung Hämatologie
AL-amyloidose
 
 
2011-000293-62: Phase II, Open, National, Multicenter Study of Bendamustine, Bortezomib (Velcade) and prednisone (BVP) in patients with newly diagnosed multiple myeloma (BenVelPres) Estudio de Fase II Abierto, Nacional, Multicéntrico de Bendamustina, Bortezomib (Velcade) y Prednisona (BVP) en Pacientes con Mieloma Múltiple de Nuevo Diagnóstico (BenVelPres)

Ongoing
2
60
Europe
Velcade, LEVACT, PREDNISONA, Velcade, LEVACT, VELCADE 3,5 mg, polvo para solución inyectable, LEVACT 2,5 mg/ml polvo para concentrado para solución para perfusión, VELCADE 3,5 mg, polvo para solución inyectable, LEVACT 2,5 mg/ml polvo para concentrado para solución para perfusión
Fundación PETHEMA, Fundación PETHEMA
MULTIPLE MYELOMA MIELOMA MÚLTIPLE
 
 
2010-018866-21: Intensified program including Bendamustine followed by PBSC mobilization and high dose therapy and autograft for patients with relapsed or resistant CD 20+ Follicular Non Hodgkin Lymphoma: a multicenter, pivotal GITIL study

Ongoing
2
20
Europe
Bendamustine Hydrochloride, ELOXATIN*IV FL POLV 100MG, Bendamustine Hydrochloride, ELOXATIN*IV FL POLV 100MG
A.I.L. (ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMI
RESISTANT FOLLICULAR NON HODGKIN LYNPHOMA
 
 
CLL2-BAG, NCT02401503 / 2014-000580-40: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL

Checkmark In combination with obinutuzumab following bendamustine
Aug 2018 - Aug 2018: In combination with obinutuzumab following bendamustine
Active, not recruiting
2
66
Europe
Bendamustine, GA101, Obinutuzumab, ABT-199, Venetoclax, GDC-0199
German CLL Study Group, Hoffmann-La Roche, AbbVie
Chronic Lymphocytic Leucemia
12/16
12/24
NCT01286272: Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Active, not recruiting
2
135
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP 18083, CEP-18083, CEP18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, VIVIMUSTA, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, LDP-341, LDP341, MLN 341, MLN-341, MLN341, PS 341, PS-341, PS341, Velcade, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Laboratory Biomarker Analysis, Ofatumumab, Arzerra, GSK1841157, HuMax-CD20, HuMax-CD20, 2F2, Kesimpta, Positron Emission Tomography with Radiolabeled Targeting Agent, Positron Emission Tomography with Radiolabeled Targeting Agents
National Cancer Institute (NCI)
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
05/17
03/25
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare

Not yet recruiting
2
130
Europe
Venclyxto, Film-coated tablet, Venclyxto
Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l.
Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
PTL, NCT02753062: Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma

Recruiting
2
22
RoW
bendamustine, rituximab, symbenda, mabthera
Asan Medical Center, Cheolwon Suh
Diffuse Large B Cell Lymphoma
08/18
08/23
NCT03623373: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Active, not recruiting
2
13
US
Bendamustine, Treanda, Bendeka, Rituximab, Rituxan, Rituxan Hycela, Acalabrutinib, Calquence®, Cytarabine, Cytosar-U, Leukapheresis, Peripheral blood, Oral rinse, Bone marrow collection
Washington University School of Medicine, Acerta Pharma BV
Mantle Cell Lymphoma
02/20
02/25
2012-003947-31: OPTIMAL: Optimising Renal Outcome in Myeloma renal failure

Not yet recruiting
2
120
Europe
Thalidomide celgene, Velcade, Levact, J9041, Capsule, hard, Injection, Infusion, Thalidomide Celgene™, Velcade, Levact
Oxford University Hospitals NHS Trust, Janssen-Cilag, NAPP Pharmaceuticals
Myeloma and renal impairment, Cancer of bone marrow, kidney disfunction, Diseases [C] - Cancer [C04]
 
 
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
CLL2-BAAG, NCT03787264 / 2017-003133-28: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL

Completed
2
46
Europe
Bendamustine, Obinutuzumab, GA101, Gazyvaro, Acalabrutinib, ACP-196, Calquence, Venetoclax, ABT-199, Venclyxto
German CLL Study Group
Chronic Lymphoid Leukemia
02/21
09/23
PrE0403, NCT03113422: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Completed
2
56
US
Induction Venetoclax, GDC-0199, ABT-199, RO5537382, Maintenance Venetoclax
PrECOG, LLC., Genentech, Inc.
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
05/21
01/23
2019-002499-14: RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a randomized phase II RELYAGE (RELAPSE LYMPHOMA AGED): ETUDE DE PHASE II RANDOMISEE EVALUANT LA SURVIE AVEC PRESERVATION DE L’AUTONOMIE DE RITUXIMAB PLUS CHIMIOTHERAPIE OU RITUXIMAB PLUS LENALIDOMIDE CHEZ DES PATIENTS AGES EN RECHUTE D’UN LYMPHOME DIFFUS A GRANDES CELLULES B

Not yet recruiting
2
114
Europe
rituximab, Capsule, hard, Powder for solution for infusion, Solution for infusion, revlimid, gemcitabine, oxaliplatine, bendamustine, Mabthera
CHU Amiens-Picardie, DGOS
diffuse large B cell lymphoma lymphome diffus à grandes cellules, lymphoma lymphome, Diseases [C] - Cancer [C04]
 
 
FIL_V-RBAC, NCT03567876: Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

Active, not recruiting
2
141
Europe
Venetoclax, Venclyxto (commercial name)
Fondazione Italiana Linfomi - ETS, AbbVie
Lymphoma, Mantle-Cell
07/21
07/25
2021-000468-32: Study for patients with mantle cell lymphoma (one type of lymphomas = lymph node cancer), aimed to answer the question if patients who relapse after previous therapy with Bruton tyrosine kinase inhibitor (type of biologivcal treatment) will be beneficiary adding of polatuzumab vedotin (new type of biological treatment) to commonly used treatment with bendamustine and rituxima (combination of chemotherpay and biological treatment) Studie pro pacienty s lymfomem z plášťových buněk (jeden z podtypů lymfomu), která se snaží odpovědět na otázku, zda u pacientů, u kterých selhala předchozí léčba inhibitory Brutonovy kinázy (typ biologické léčby), bude přinosem přidání polatuzumab vedotinu (nový typ biologické léčby) k již běžně používané záchranné léčbě (kombinace bendamustinu a rituximabu (tj. chemoterapie a biologické léčby)

Not yet recruiting
2
21
RoW
Polatuzumab vedotin, Bendamustine Accord 25 mg/ml, Mabthera, RO5541077, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustine Accord, Mabthera
Kooperativní lymfomová skupina, z.s., Kooperativní lymfomová skupina, z.s.
Mantle cell lymphoma lymfom z plášťových buněk, aggressive lymph node cancer of B-cell origin agresivní nádorové onemocnění z mízních uzlin z B-buněk, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
2021-002630-17: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine andDexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patientsHodgkin resistant to treatment of 1 line.

Not yet recruiting
2
84
Europe
Nivolumab, Concentrate for solution for infusion, OPDIVO
Medical Unicersity of Gdansk, Medical Research Agency
Refractory / relapsed Hodgkin's lymphoma Oporny/nawrotowy chłoniak Hodgkina, Refractory / relapsed Hodgkin's lymphoma, Diseases [C] - Cancer [C04]
 
 
CLL2-BCG, NCT02445131 / 2014-000582-47: Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL

Completed
2
48
Europe
Bendamustine, GA101, Obinutuzumab, CAL-101, Idelalisib
German CLL Study Group, Hoffmann-La Roche, Gilead Sciences
Chronic Lymphocytic Leucemia
03/22
03/22
2021-006030-40: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA

Not yet recruiting
2
16
Europe
Powder for solution for infusion, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Polivy, Bendamustin Accord, MabThera
Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
MANTLE CELL LYMPHOMA, MANTLE CELL LYMPHOMA, Diseases [C] - Cancer [C04]
 
 
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Completed
2
33
US
Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan
PrECOG, LLC., Genentech, Inc.
Mantle Cell Lymphoma
10/22
07/24
NCT01059786: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Checkmark P2 data in HCL
Nov 2011 - Nov 2011: P2 data in HCL
Active, not recruiting
2
69
US
Pentostatin, Nipent, Rituximab, Rituxan, Bendamustine, Bendeka, Treanda, Acetaminophen, Tylenol, Diphenhydramine, Benadryl, Epinephrine, Adrenaline, Antihistamines, Corticosteroids, Corticoid, Bronchodilators, Broncholytic, Intravenous (IV) Saline
National Cancer Institute (NCI)
Hairy Cell Leukemia
12/22
12/25
2020-002935-30: Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma. Venetoclax in Kombination mit Ibrutinib und Rituximab oder konventionelle Chemotherapie (Bendamustin) und Ibrutinib und Rituximab bei Patienten mit Mantelzell-Lymphoms.

Not yet recruiting
2
150
Europe
Film-coated tablet, IMBRUVICA®140 mg Filmtabletten, Venclyxto® 10 mg Filmtabletten, Venclyxto® 50 mg Filmtabletten, Venclyxto® 100 mg Filmtabletten
University Medical Center of the Johannes Gutenberg-University Mainz, AbbVie Inc., Janssen Pharmaceutica NV
Mantle Cell Lymphoma Mantelzell-Lymphom, malignant lymph node disease bösartige Lymphknotenerkrankung, Diseases [C] - Cancer [C04]
 
 
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Checkmark Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014)
Checkmark For newly diagnosed Hodgkin's lymphoma in elderly patients
Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients
Checkmark ASH 2013
More
Completed
2
131
Canada, US
brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab
Seagen Inc., Bristol-Myers Squibb
Hodgkin Disease, Peripheral T Cell Lymphoma
04/23
09/23
FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting
2
37
Europe
Copanlisib, ALIQOPA
Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
12/24
12/24
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
NCT01437709: Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Completed
2
30
US
Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
Memorial Sloan Kettering Cancer Center, GlaxoSmithKline
Mantle Cell Lymphoma
09/23
09/23
BURGUND, NCT03615664: The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

Active, not recruiting
2
115
Europe
Bendamustine, Treanda, Gemcitabine, Gemzar, Dexamethasone, PET/CT, Autologous Stem Cell Transplant, ASCT
Polish Lymphoma Research Group
Hodgkin's Lymphoma
06/24
09/24
NCT04217317: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Terminated
2
6
US
CPI 613, devimistat, Bendamustine, Bendeka, Treanda, Bendamustine Hydrochloride
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
04/23
07/24
NCT06136351: A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Recruiting
2
23
RoW
Zanubrutinib, Rituximab, Bendamustin
Ruijin Hospital
Lymphoma, Mantle-Cell
11/27
11/27
NCT06415708: Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Recruiting
2
134
RoW
Obinutuzumab Combined With Bendamustine
Institute of Hematology & Blood Diseases Hospital, China
B Cell Lymphoma
11/24
06/26
NCT03609593: Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

Active, not recruiting
2
42
US
Bendamustine, Treanda, Venetoclax, ABT-199, Venclexta, Rituximab, Rituxan
Nicole Lamanna
Chronic Lymphocytic Leukemia
01/25
12/25
 

Download Options